Allianz Asset Management
CBIO

Allianz Asset Management’s Crescent Biopharma CBIO Stock Holding History

Allianz Asset Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,999
Closed -$2.38M – 2752
2019
Q2 		$2.38M Sell
1,999
-272
-12% -$325K ﹤0.01% 1827
2019
Q1 		$2.83M Buy
2,271
+1,129
+99% +$1.29M ﹤0.01% 1701
2018
Q4 		$1.08M Sell
1,142
-42
-4% -$50.5K ﹤0.01% 1998
2018
Q3 		$1.71M Buy
1,184
+1,073
+967% +$1.62M ﹤0.01% 2008
2018
Q2 		$178K Sell
111
-623
-85% -$1.07M ﹤0.01% 2578
2018
Q1 		$1.19M Buy
+734
New +$1.53M ﹤0.01% 2136

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Allianz Asset Management's CBIO Position: Q3 2019 in Review

Allianz Asset Management sold out of Crescent Biopharma (CBIO) in Q3 2019, closing a stake of 1,999 shares — an estimated $2.38M sold.

Allianz Asset Management first reported a position in CBIO in Q1 2018 and held it in 6 quarters. The position peaked at $2.83M in Q1 2019. 75 funds tracked by Wall St. Rank hold CBIO as of Q3 2019.

  • Allianz Asset Management reported no remaining Crescent Biopharma position as of Q3 2019 after selling out during the quarter.
  • Allianz Asset Management sold 1,999 Crescent Biopharma shares in Q3 2019, an estimated $2.38M.
  • Allianz Asset Management first reported a position in Crescent Biopharma in Q1 2018 and held it in 6 quarters.
  • Allianz Asset Management's Crescent Biopharma position peaked at $2.83M in Q1 2019.
  • 75 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2019.

Based on Allianz Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.